Professor Laurence Egan research specialises in Optimized therapy of complicated and refractory inflammatory bowel disease.
Professor Egan has elucidated the role of the pivotal pro-inflammatory carcinogenic transcription factor nuclear factor-κB in intestinal homeostasis and disease. This work has provided insights into the pathogenesis of colitis-associated colon cancer, radiation colitis and intestinal ischaemia-reperfusion injury. His translational research focuses on elucidating the mechanisms of action and resistance to biologic therapies used in inflammatory bowel disease.
Current research is developing novel strategies for the localized delivery of drugs to perianal fistulas that complicate Crohn’s disease. This work will develop a novel drug-eluting device to optimize this difficult-to-treat and common clinical problem.
The clinical tartgets focused on are inflammatory bowel disease, especially complicated and refractory disease.
Prof Egans achievements include Characterization of the role of transcription factor NFκB in intestinal homeostasis and disease pathogenesis, Elucidation of aspects of the pathogenesis of colitis-associated colon cancer. Establishment and Interim Director of HRB Clinical Research Facility Galway.
He has over 70 peer-reviewed publications in the field of inflammatory bowel disease research. 7500 citations, H-index 34 (Google Scholar). 51 Invited Lectures/Visiting Professorships; 1999, J. Arnold Bargen Award from Mayo Clinic; 2004, American Gastroenterological Association Regal Award; 2010, elected to Association of Physicians of Great Britain and Ireland; 2012, co-organizer Keystone Symposium, Role of inflammation in carcinogenesis; 2012, Founding Council member of Irish Academy of Medical Sciences; 2014, appointed Editor in Chief of the Journal of Crohn’s and Colitis. 2017-2019, President, Irish Society of Gastroenterology.
+353 (0) 91 495833